Studies have successfully shown that targeting CCL2 signaling using neutralizing antibody to CCL2 can significantly inhibit PCa tumor growth and migration in vivo including both VCaP (the only endogenously T/E fusion expressing PCa cell line) subcutaneous and intratibial injection models [39, 45]. The gene discussed is CCL2; the disease is neoplasm.